BioSpace News Archive

Optinose today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.

Pressure BioSciences, Inc. today announced that VST has increased its existing purchase order with PBIO by 10-fold (from 500 to 5,000 bottles), effective immediately.

The U.S. National Science Foundation announced a highly competitive five-year award to Battelle for the continued operations and maintenance of the National Ecological Observatory Network.

All director nominees reelected and all other company proposals approved by shareholders

Soligenix, Inc. announced that its 2023 Annual Meeting of Stockholders scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 7, 2023.

Achilles Therapeutics plc disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.

RedHill Biopharma Ltd. announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC indicating that, for the thirty consecutive business days from August 7, 2023, to September 18, 2023, the bid price for the Company’s American Depositary Shares had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450.

Vicarious Surgical Inc. announced that on September 20, 2023, it received a notice from the New York Stock Exchange that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period.

Coherus BioSciences, Inc., announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 109,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $4.51, the closing trading price on the grant date.